13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25–33 Years with Minor Cytological Abnormalities–6 Years of Follow-Up
International Journal of Environmental Research and Public Health · 2023
DOI: 10.3390/ijerph20054119 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Amir Rad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine & Department of Clinical Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Atypical Squamous Cells of the Cervix, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A specific, cost-effective triage test for minor cytological abnormalities is essential for cervical cancer screening among younger women to reduce overmanagement and unnecessary healthcare utilization. We compared the triage performance of one 13-type human papillomavirus (HPV) DNA test and one 5-type HPV mRNA test.
Methods
We included 4115 women aged 25–33 years with a screening result of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) recorded in the Norwegian Cancer Registry during 2005–2010. According to Norwegian guidelines, these women went to triage (HPV testing and repeat cytology: 2556 were tested with the Hybrid Capture 2 HPV DNA test, which detects the HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; and 1559 were tested with the PreTect HPV-Proofer HPV mRNA test, which detects HPV types 16, 18, 31, 33, and 45). Women were followed through December 2013.
Results
HPV positivity rates at triage were 52.8% and 23.3% among DNA- and mRNA-tested women (p < 0.001), respectively. Referral rates for colposcopy and biopsy and repeat testing (HPV + cytology) after triage were significantly higher among DNA-tested (24.9% and 27.9%) compared to mRNA-tested women (18.3% and 5.1%), as were cervical intraepithelial neoplasia grade 3 or worse (CIN3+) detection rates (13.1% vs. 8.3%; p < 0.001). Ten cancer cases were diagnosed during follow-up; eight were in DNA-tested women.
Conclusion
We observed significantly higher referral rates and CIN3+ detection rates in young women with ASC-US/LSIL when the HPV DNA test was used at triage. The mRNA test was as functional in cancer prevention, with considerably less healthcare utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Community Medicine & Department of Clinical Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway.
- Department of Pathology, University Hospital of North Norway, 9019 Tromsø, Norway.
- Department of Community Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway.
ORCID-Profile: Sveinung Wergeland Sørbye, Tormod Brenn, Sweta Tiwari, Maja-Lisa Løchen, Finn Egil Skjeldestad
Zitieren
APA
Rad, A., Sørbye, S. W., Brenn, T., Tiwari, S., Løchen, M. L., & Skjeldestad, F. E. (2023). 13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25–33 Years with Minor Cytological Abnormalities–6 Years of Follow-Up. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20054119
Vancouver
Rad A, Sørbye SW, Brenn T, Tiwari S, Løchen ML, Skjeldestad FE. 13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25–33 Years with Minor Cytological Abnormalities–6 Years of Follow-Up. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20054119
BibTeX
@article{Rad2023,
author = {Rad, Amir and Sørbye, Sveinung Wergeland and Brenn, Tormod and Tiwari, Sweta and Løchen, Maja-Lisa and Skjeldestad, Finn Egil},
title = {13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25–33 Years with Minor Cytological Abnormalities–6 Years of Follow-Up},
journal = {International Journal of Environmental Research and Public Health},
year = {2023},
doi = {10.3390/ijerph20054119}
}
EUVIMED